1. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
- Author
-
Michael Fuchs, Andreas Engert, Stephanie Sasse, Elena Gerhard-Hartmann, Sven Borchmann, Arjan Diepstra, Alberto Zamò, Tabea Steinmüller, Peter Borchmann, Johanna Grund, Johanna Veldman, Wolfram Klapper, Sarah Reinke, Susana Ben-Neriah, Anja Mottok, Helen Goergen, Paul J Bröckelmann, Andreas Rosenwald, and Stem Cell Aging Leukemia and Lymphoma (SALL)
- Subjects
DNA Copy Number Variations ,BLOCKADE ,MULTICENTER ,Locus (genetics) ,Major histocompatibility complex ,B7-H1 Antigen ,Translocation, Genetic ,BRENTUXIMAB VEDOTIN ,Refractory ,Germany ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,SINGLE-ARM ,Humans ,CD274 ,FAILURE ,Medicine ,Genetic Predisposition to Disease ,ddc:610 ,Stage (cooking) ,Brentuximab vedotin ,DIAGNOSTIC-TOOL ,Genetic Association Studies ,In Situ Hybridization, Fluorescence ,fluorescence in situ hybridisation ,biology ,TRANSPLANTATION ,business.industry ,Disease Management ,NIVOLUMAB ,MULTICOHORT ,Hematology ,immune checkpoint blockade ,Prognosis ,Ligand (biochemistry) ,Combined Modality Therapy ,Hodgkin Disease ,Immunohistochemistry ,major histocompatibility complex ,Transplantation ,Treatment Outcome ,classical Hodgkin lymphoma ,biology.protein ,Cancer research ,PD-L1 IMMUNOHISTOCHEMISTRY ,Nivolumab ,Chromosomes, Human, Pair 9 ,business ,medicine.drug - Abstract
High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed-Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.
- Published
- 2021
- Full Text
- View/download PDF